| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.9M | — | +70.1% |
| SG&A Expense | $1.9M | — | -0.8% |
| Operating Income | -$4.9M | — | -32.5% |
| Pre-tax Income | -$2.9M | — | +19.5% |
| Net Income | -$2.9M | — | +19.5% |
| EPS (Basic) | -$0.12 | — | +92.5% |
| EPS (Diluted) | -$0.12 | — | +92.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $50.4M | -8.6% | +843.6% |
| Current Assets | $52.7M | -6.6% | +760.9% |
| Total Assets | $56.4M | -6.4% | +284.4% |
| Current Liabilities | $1.5M | -70.1% | -6.6% |
| Total Liabilities | $1.5M | -69.3% | -8.2% |
| Stockholders' Equity | $54.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.8M | — | -56.7% |
| Financing Cash Flow | $750 | — | -99.9% |
| +322.3% |